Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654355 | 0.88 | CA12 (0.48) | ALDH1A1HPGDCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5766581 | 0.86 | CA1 (0.51) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL1936202 | 0.86 | MGLL (0.55) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL30754110 | 0.84 | NPC1 (0.47) | CA1CA2HDAC1HDAC6NPC1 | |
| SCHEMBL20581863 | 0.83 | HPGD (0.46) | ALDH1A1HPGDCA1CA2LMNA | |
| SCHEMBL7328495 | 0.82 | CTSK (0.50) | CA1CA12CA7CA14MAPT | |
| SCHEMBL4465651 | 0.82 | MGLL (0.51) | CYP4A11CYP4F2LOXL2MGLLCA1 | |
| SCHEMBL1054945 | 0.82 | CYP4A11 (0.58) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL4082188 | 0.81 | MAPT (0.59) | CA1CA2CA12CA9MAPT | |
| SCHEMBL5983006 | 0.81 | CYP4A11 (0.57) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565565-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028601-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7863312-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | MERCK SERONO SA (CH) | 2011-01-04 | — | — | US | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | LABORATOIRES SERONO S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-7410991-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | LABORATOIRES SERONO S.A. (CH) | 2008-08-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1244661-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047926-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | PTGER4, PTGER2, PTGER1 | CYP4A11 130/4885CYP4F2 385/4885LOXL2 1792/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | CYP4A11 56/4885CYP4F2 781/4885LOXL2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.